Related references
Note: Only part of the references are listed.
Article
Multidisciplinary Sciences
Bo Meng et al.
Summary: The Omicron variant of SARS-CoV-2 has a higher affinity for ACE2 and can evade neutralizing antibodies more effectively compared to the Delta variant. A third dose of mRNA vaccine can provide enhanced protection. Omicron has lower replication in lung and gut cells and less efficiently cleaves its spike protein compared to Delta.
Article
Biochemistry & Molecular Biology
Samuel M. S. Cheng et al.
Summary: Specific antibody levels against the SARS-CoV-2 Omicron variant decrease significantly after two doses of BNT162b2 or CoronaVac vaccines, but can be markedly increased with a booster dose of BNT162b2. Individuals who previously received two doses of BNT162b2 or CoronaVac showed reduced serum antibody titers against Omicron, while a BNT162b2 booster dose increased the antibody levels in the majority of individuals. This suggests mRNA vaccine boosters may be necessary in countries primarily using CoronaVac vaccines to combat the spread of Omicron.
Article
Medicine, General & Internal
R. L. Atmar et al.
Summary: This study investigated the efficacy of homologous and heterologous booster vaccines in adults who had completed a primary Covid-19 vaccine regimen. The results showed that both types of booster vaccines were safe and immunogenic.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Medicine, General & Internal
Lianpan Dai et al.
Summary: The ZF2001 vaccine has been shown to be safe and effective against symptomatic and severe-to-critical Covid-19 in a large cohort of adults for at least 6 months after full vaccination.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Letter
Medicine, General & Internal
Jingyou Yu et al.
Summary: Although immunity from two doses of BNT162b2 vaccine diminishes over time, a booster dose significantly enhances the neutralizing antibodies against both the BA.1 and BA.2 variants.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Public, Environmental & Occupational Health
Alejandro Jara et al.
Summary: This study evaluated the effectiveness of booster vaccine doses against COVID-19 in individuals who had completed a primary immunisation schedule with CoronaVac. The results showed that a homologous or heterologous booster dose provides a high level of protection against COVID-19, including severe disease and death. Heterologous boosters showed higher vaccine effectiveness than a homologous booster for all outcomes, providing additional support for a mix-and-match approach.
LANCET GLOBAL HEALTH
(2022)
Letter
Biochemistry & Molecular Biology
Zhongcheng Zhou et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY
(2021)
Article
Multidisciplinary Sciences
Jingyun Yang et al.
